Socio-Economic Considerations in Biotechnology Regulation, Karinne Ludlow; Stuart J. Smyth; Jos? Falck-Zepeda

Автор: Ferrari
Название: Antisense-Based Drugs and Therapeutics: Preclinica l and Clinical Considerations for Development
ISBN: 1118537335 ISBN-13(EAN): 9781118537336
Издательство: Wiley
Рейтинг:
Цена: 188970.00 T
Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: Antisense-based drugs are part of a growing number of pharmaceutical and biotech programs to treat diseases including cancer, diabetes, and ALS. Reviewing fundamentals and offering guidelines for drug discovery and development, this book is a practical guide from the safety assessment to clinical experience with antisense oligonucleotides.

Автор: Andrew A. Udy; Jason A. Roberts; Jeffrey Lipman
Название: Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill
ISBN: 9811053359 ISBN-13(EAN): 9789811053351
Издательство: Springer
Рейтинг:
Цена: 111790.00 T
Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: This book provides unique insights into the issues that drive modified dosing regimens for antibiotics in the critically ill.

Автор: Chris A. Wozniak; Alan McHughen
Название: Regulation of Agricultural Biotechnology: The United States and Canada
ISBN: 9400796927 ISBN-13(EAN): 9789400796928
Издательство: Springer
Рейтинг:
Цена: 156720.00 T
Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: Based upon vast experience interacting with the regulatory system, the editors and authors offer demystifying views of the US and Canadian regulatory structures and how they came to be.

Автор: Karinne Ludlow; Stuart J. Smyth; Jos? Falck-Zepeda
Название: Socio-Economic Considerations in Biotechnology Regulation
ISBN: 1493943855 ISBN-13(EAN): 9781493943852
Издательство: Springer
Рейтинг:
Цена: 102480.00 T
Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: It includes an overview of the inclusion of SEC assessment in the regulation of LMOs that looks at the rationale for the inclusion of SECs, in the context of the existing science-based risk assessment systems.